Esther Clinical Trial for Glaucoma and Ocular Hypertensive Patients

The Esther study will compare an investigational preservative-free eyedrop with a preserved treatment alternative currently available. These eyedrops are used to reduce eye (intraocular) pressure, to help protect the vision and quality of life for people with glaucoma or ocular hypertension.

Both eyedrop solutions being compared contain the same active ingredient, called bimatoprost, so your glaucoma or ocular hypertension will continue to be treated during the study.

The Esther study will last for up to 18 weeks and is designed to have minimum impact on your daily life with only five visits to a study doctor at the clinic site. Treatment, eye exams and appointments will be provided free of charge.